1071864-06-6

Basic information

• Product Name: 3-{2-[4-(6-fluoro-1,2-benzoisoxazol-3-yl)-piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydro-pyrido[1,2-α]pyrimidin-9-yl benzoate
• Synonyms: 3-{2-[4-(6-fluoro-1,2-benzoisoxazol-3-yl)-piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydro-pyrido[1,2-α]pyrimidin-9-yl benzoate
• CAS NO: 1071864-06-6
• Molecular Weight: 530.599
• Mol File: 1071864-06-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-{2-[4-(6-fluoro-1,2-benzoisoxazol-3-yl)-piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydro-pyrido[1,2-α]pyrimidin-9-yl benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-{2-[4-(6-fluoro-1,2-benzoisoxazol-3-yl)-piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydro-pyrido[1,2-α]pyrimidin-9-yl benzoate(1071864-06-6)
• EPA Substance Registry System: 3-{2-[4-(6-fluoro-1,2-benzoisoxazol-3-yl)-piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydro-pyrido[1,2-α]pyrimidin-9-yl benzoate(1071864-06-6)

Safety Data

• Hazardous Substances Data: 1071864-06-6(Hazardous Substances Data)

Upstream product

• 98-88-4 benzoyl chloride 
• 144598-75-4 paliperidone 
• 130049-87-5 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-ol acetate(ester) 
• 1312573-55-9 9-O-propionyl paliperidone 

Downstream Products

• 144598-75-4 paliperidone 
• 1312573-56-0 9-O-phenylacetyl chloride paliperidone 

Relevant articles and documents

Novel Process for the Preparation of Paliperidone

The present invention relates to a novel process for the preparation of paliperidone by hydrolysis of 9-O-acylated paliperidone. In a preferred embodiment of the present invention, Paliperidone Form (II) of purity of about 98% or more was obtained by basic hydrolysis of 9-O-Acetyl Paliperidone.

NOVEL COMPOUNDS FOR TREATMENT OF PSYCHOTIC DISORDERS, PREPARATION METHODS AND USES THEREOF

The present invention relates to a compound of formula (I), an optical isomer or a pharmaceutically acceptable salt thereof, its preparation and uses, wherein R is defined as herein. Such compounds can be presented as an optical isomer or a racemic mixture. The compounds can be metabolized in vivo to form a pharmacologically active substance as antagonist of neurotransmitters, and can be used for the treatment of the related mental disorders such as schizophrenia.